Results 61 to 70 of about 2,343,487 (194)

TROP2‐Targeting Chimeras (TRTACs) for Tumor Cell‐Selective Membrane Protein Degradation and Enhanced Drug Delivery

Advanced Science, EarlyView.
TROP2 is identified as a novel tumor‐selective lysosomal‐targeting receptor with established clinical relevance. TROP2‐targeting chimeras (TRTACs) are developed by genetically fusing a TROP2‐binding nanobody to nanobodies against specific target proteins.
Luping Chen, Xinying Fu, Wenqian Dong, Xiaobei Deng, Simin Chen, Fujun Wang, Jian Zhao, Shiqun Shao, Liqiang Fan, Jingyu Zhang, Lixin Zhang   +10 more
wiley   +1 more source

Drug resistance to tamoxifen: mutant estrogen receptors as a potential mechanism of tamoxifen-stimulated tumor growth

, 1995
INTRODUCTION Tamoxifen is the endocrine treatment of choice for all stages of breast cancer (Jordan 1993). The adjuvant use of tamoxifen produces survival advantages and prevents the appearance of a second primary
V C Jordan, W L Catherino, D M Wolf
core   +1 more source

Tracking CDK1 Dynamics With a Novel Biosensor Mouse and Clinical Cohorts to Predict CDK4/6 Inhibitor Sensitivity in ER+ Breast Cancer

Advanced Science, EarlyView.
Cyclin‐dependent kinase (CDK) 1 activity is a dynamic marker of treatment response in estrogen receptor positive breast cancer. Patient cohorts reveal CDK1 activity increases during progression to invasive disease, where high expression correlates with poor survival. Using a novel Cdk1 biosensor mouse alongside in vitro models, we demonstrate that CDK1
Sarah Alexandrou, Kristine J. Fernandez, Min Li Huang, Ewan K. A. Millar, Claire Vennin, Leila Eshraghi, Tan Dat Timothy Lam, Victoria Lee, Nyah C. Brooks, Janett Stoehr, Cristian Guaman Mendez, Douglas Strathdee, David Stevenson, David Herrmann, Sandra O'Toole, Paul Timpson, Max Nobis, C. Elizabeth Caldon   +17 more
wiley   +1 more source

Sox2 promotes tamoxifen resistance in breast cancer cells

EMBO Molecular Medicine, 2013
Development of resistance to therapy continues to be a serious clinical problem in breast cancer management. Cancer stem/progenitor cells have been shown to play roles in resistance to chemo‐ and radiotherapy.
Marco Piva, Giacomo Domenici, Oihana Iriondo, Miriam Rábano, Bruno M Simões, Valentine Comaills, Inmaculada Barredo, Jose A López‐Ruiz, Ignacio Zabalza, Robert Kypta, Maria d M Vivanco   +10 more
doaj   +1 more source

Cannabinoid CB1 Receptor in Nociceptors Mediates Postoperative Analgesia via ASIC3 Inhibition

Advanced Science, EarlyView.
CB1R and ASIC3 are co‐expressed in CGRP+ nociceptors of mouse DRG. Plantar incision triggers an upregulation of ASIC3 and activation of ASIC3+ neurons, driving mechanical allodynia. CB1R activation suppresses ASIC3 function and downstream ERK1/2 phosphorylation, thereby braking nociceptive signaling and accelerating pain resolution.
Kangtai Xu, Luyao Ji, Haoyi Yang, Xiying Chen, Qiaodan Hu, Haimei He, Jiawei Wu, Leyan Shan, Shihui Feng, Yingzhi Li, Xiongchang Tan, Hao Wang, Zilong Wang, Chaoran Wu   +13 more
wiley   +1 more source

ROLE OF TRANSFORMING GROWTH FACTOR RECEPTOR B I TYPE (TGF-BRI) IN THE PROGRESSION OF THE LUMINAL BREAST CANCER SUBTYPE

Сибирский онкологический журнал, 2017
Introduction. The crosstalk between the estrogen and growth factor receptors signaling may play an important role in the resistance to endocrine therapy.
N. N. Babyshkina, S. V. Vtorushin, T. A. Dronova, N. V. Krakhmal, M. V. Zavyalova, M. M. Tsyganov, S. V. Patalyak, E. M. Slonimskaya, N. V. Cherdyntseva   +8 more
doaj   +1 more source

Estrogen Receptor Regulates E2F1 Expression to Mediate Tamoxifen Resistance

, 2010
Antiestrogen resistance often develops with prolonged exposure to hormone therapies, including tamoxifen, and is a major problem in the treatment of breast cancer.
McClellan, Ashley, Louie, Maggie C., Swift, Christina, Kawabata, Lauren   +3 more
core   +1 more source

Acinar‐Derived Organoids Reveal Stage‐Specific Control of Acinar Plasticity

Advanced Science, EarlyView.
An acinar‐derived organoid system maintains adult pancreatic acinar identity ex vivo, converts it along an ordered acinar‐to‐ductal‐like trajectory, and then partially restores it. Each transition carries its own signal requirement, with EGF/EGFR initiating conversion and a staged glucocorticoid–IGF1R switch driving redifferentiation.
Yongfei Hou, Siyu Li, Chunying Li, Zhifan Lin, Dan He, Li Yang, Liping Fu, Qianyue Zhang, Tianping Zhou, Yao Yao, Xiaolei Yin   +10 more
wiley   +1 more source

Dual Effects of β‐TrCP2 Deletion in Bone Homeostasis: Suppression of Osteoclastogenesis and Enhancement of Osteoblast Activity

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to elucidate the role of beta‐transducin repeat‐containing protein 2 (β‐TrCP2) in bone homeostasis for its potential as a therapeutic target for osteoporosis. Methods The role of β‐TrCP2 in bone phenotypes was investigated using systemic β‐TrCP1 knockout (KO) and β‐TrCP2KO mice, along with myeloid‐specific ...
Woo Jung Kim, Sora Han, Hye In Ka, Sun Young Lee, Jiwon Kim, Hyunjeong Joo, Sujung Soh, Gaeun Oh, Kyung Hyun Yoo, Seung Hyun Han, Yeongkag Kwon, Choogon Lee, Kyung‐Hyun Park‐Min, Se Hwan Mun, Young Yang   +14 more
wiley   +1 more source

Cancer-associated fibroblast promotes tamoxifen resistance in estrogen receptor positive breast cancer via exosomal LncRNA PRKCQ-AS1/miR-200a-3p/MKP1 axis-mediated apoptosis suppression

Journal of Experimental & Clinical Cancer Research
Background Tamoxifen resistance remains a significant challenge in the endocrine therapy of estrogen receptor-positive (ER+) breast cancer. Cancer-associated fibroblasts (CAFs) facilitate therapeutic resistance through exosome secretion, yet the role of ...
Chenghui Wu, Xi Sun, Yujie Lu, Haoyu Wang, Zhengyuan Yu, Zheng Wang, Renhong Huang, Yihua Jin, Xing Chen, Haixia Xie, Yu Zong, Kunwei Shen, Min Jiang, Yujie Tang, Xiaosong Chen   +14 more
doaj   +1 more source